NDAOPHTHALMICSOLUTION/DROPS
Approved
Jul 1946
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
SODIUM SULAMYD (sulfacetamide sodium) by Merck & Co. is clinical pharmacology the most widely accepted mechanism of action of sulfonamides is the woods-fildes theory, which is based on the fact that sulfonamides act as competitive antagonists to para-aminobenzoic acid (paba), an essential component for bacterial growth. Approved for the topical control of acne vulgaris, acne rosacea, seborrheic dermatitis. First approved in 1946.
Drug data last refreshed 14h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Sodium Sulamyd is a sulfonamide antibiotic and sulfur-based topical ophthalmic solution approved in 1946 for bacterial eye infections and inflammatory ocular conditions. It works as a competitive antagonist to para-aminobenzoic acid (PABA), inhibiting bacterial growth, while sulfur components suppress Propionibacterium acnes and free fatty acid formation. The drug is indicated for topical ocular use in bacterial conjunctivitis and related conditions.
LOE Approaching
As an older established product approaching loss of exclusivity with moderate competitive pressure (30%), brand teams are likely consolidating and shifting focus to defending market share rather than growth.
Mechanism of Action
CLINICAL PHARMACOLOGY The most widely accepted mechanism of action of sulfonamides is the Woods-Fildes theory, which is based on the fact that sulfonamides act as competitive antagonists to para-aminobenzoic acid (PABA), an essential component for bacterial growth. While absorption through intact…
Indications (3)
Worked on SODIUM SULAMYD at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.